CN102171219A - 吡啶衍生物的晶型 - Google Patents

吡啶衍生物的晶型 Download PDF

Info

Publication number
CN102171219A
CN102171219A CN2009801393221A CN200980139322A CN102171219A CN 102171219 A CN102171219 A CN 102171219A CN 2009801393221 A CN2009801393221 A CN 2009801393221A CN 200980139322 A CN200980139322 A CN 200980139322A CN 102171219 A CN102171219 A CN 102171219A
Authority
CN
China
Prior art keywords
compound
formula
methylbenzenesulfonate
disorders
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801393221A
Other languages
English (en)
Chinese (zh)
Inventor
克莱尔·L·安德顿
戴维·克拉彭
龙尼·M·劳伦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nil Medical Co Ltd
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN102171219A publication Critical patent/CN102171219A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2009801393221A 2008-08-05 2009-08-04 吡啶衍生物的晶型 Pending CN102171219A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative
GB0814340.6 2008-08-05
PCT/EP2009/060089 WO2010015626A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
CN102171219A true CN102171219A (zh) 2011-08-31

Family

ID=39767571

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801393221A Pending CN102171219A (zh) 2008-08-05 2009-08-04 吡啶衍生物的晶型

Country Status (14)

Country Link
US (1) US8093242B2 (https=)
EP (1) EP2321324A1 (https=)
JP (1) JP2011529942A (https=)
KR (1) KR20110052686A (https=)
CN (1) CN102171219A (https=)
AU (1) AU2009279135B2 (https=)
BR (1) BRPI0917224A2 (https=)
CA (1) CA2733235A1 (https=)
EA (1) EA201170300A1 (https=)
GB (1) GB0814340D0 (https=)
IL (1) IL210777A0 (https=)
MX (1) MX2011001414A (https=)
WO (1) WO2010015626A1 (https=)
ZA (1) ZA201100426B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639536B (zh) * 2009-08-27 2015-03-18 尼尔医疗有限公司 吡啶衍生物的无水晶型
EP3574907B1 (en) * 2015-05-18 2023-08-23 KaNDy Therapeutics Limited A dual nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases
JP7433252B2 (ja) 2018-03-14 2024-02-19 キャンディ・セラピューティクス・リミテッド Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤
KR102950227B1 (ko) 2019-11-15 2026-04-08 칸디 테라퓨틱스 리미티드 Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1270959A (zh) * 1999-02-24 2000-10-25 弗·哈夫曼-拉罗切有限公司 4－苯基－吡啶衍生物
WO2005002577A1 (en) * 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265209T1 (de) 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1270959A (zh) * 1999-02-24 2000-10-25 弗·哈夫曼-拉罗切有限公司 4－苯基－吡啶衍生物
WO2005002577A1 (en) * 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders

Also Published As

Publication number Publication date
US20110136798A1 (en) 2011-06-09
CA2733235A1 (en) 2010-02-11
BRPI0917224A2 (pt) 2015-11-24
EP2321324A1 (en) 2011-05-18
MX2011001414A (es) 2011-04-04
ZA201100426B (en) 2012-03-28
US8093242B2 (en) 2012-01-10
JP2011529942A (ja) 2011-12-15
GB0814340D0 (en) 2008-09-10
IL210777A0 (en) 2011-03-31
WO2010015626A1 (en) 2010-02-11
AU2009279135A1 (en) 2010-02-11
EA201170300A1 (ru) 2011-08-30
AU2009279135B2 (en) 2012-09-13
KR20110052686A (ko) 2011-05-18

Similar Documents

Publication Publication Date Title
AU2017250302B2 (en) Inhibitors of activin receptor-like kinase
CN102639536B (zh) 吡啶衍生物的无水晶型
EP3029039B1 (en) Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
AU2017382360A1 (en) Compounds, compositions and methods of use
CN102171219A (zh) 吡啶衍生物的晶型
HK1225719A1 (en) Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl) benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
AU2015315960B2 (en) Compounds as CRTH2 antagonist and uses thereof
CN102066376B (zh) 马来酸欧维特的无水晶型
TW202142541A (zh) 用作激酶抑制劑的化合物及其應用
CA3160035A1 (en) Inhibitors of adrenoreceptor adrac2
AU2009267159A1 (en) Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
CN105732659B (zh) 硝基咪唑类化合物及其制备方法和在制药中的用途
TWI773987B (zh) 二胺基嘧啶類化合物或其水合物的固體形式及其製備方法和用途
AU2022381097A1 (en) 2-(aryl-2-yl) morpholine and deuterated derivative thereof, preparation method therefor and application thereof
WO2017058689A1 (en) Crystal forms of a m1 receptor positive allosteric modulator
TW202421127A (zh) ５Ｈ－吡咯并〔２，３－ｄ〕嘧啶－６（７Ｈ）－酮及其鹽體之結晶
HK1183034B (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NIL MEDICAL CO., LTD.

Free format text: FORMER OWNER: SMITHKLINE BEECHAM CORP.

Effective date: 20130624

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130624

Address after: Steve Niki

Applicant after: Nil Medical Co., Ltd.

Address before: American Pennsylvania

Applicant before: Smithkline Beecham Corp.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110831